Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Pharmaceuticals Reports Increased Revenues for Q3

NEW YORK, Nov. 12 (GenomeWeb News) - Genaissance Pharmaceuticals of New Haven, Conn., today reported revenues of $2.6 million for the third quarter ending Sept. 30, an increase of 47 percent over revenues of $1.8 million for the year-ago quarter.


The company cited the was primarily based on revenues from DNA Sciences. Genaissance purchased the assets of DNA Sciences, which filed for Chapter 11 bankruptcy, for $1.35 million in May.


For the quarter, Genaissance reported a net loss of $5.8 million, compared to $5.2 million for the third quarter 2002.


Research and development expenses were $6.1 million for the quarter, compared to $4.7 million for the year-ago quarter.


The company reported cash, cash equivalents, and marketable securities of $17 million on hand as of Sept. 30.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.